A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose- Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects With Previously Treated Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2018
At a glance
- Drugs GBR 1342 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 05 Jun 2018 Study design was presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 25 May 2018 According to a Glenmark Pharmaceuticals media release, data from this trial will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (2018).
- 06 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.